HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC. Harvard Apparatus Regenerative Technology Inc.
Equities
HRGN
US09074M2026
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.32 USD | +3.11% |
|
-5.69% | -53.51% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to the Biostage Q1 2022 con...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patientâs own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma, or birth defects. The Company is targeting the conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy and birth defects. Its additional product candidates in its development pipeline are targeted at the reconstruction of the colon and uterus wound repair. Its product candidate includes Cellspan Esophageal Implant, and Cellspan Bronchial Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -53.51% | 33.21M | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| -0.04% | 63.19B | |
| +13.73% | 52.26B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B |
- Stock Market
- Equities
- HRGN Stock
- News Harvard Apparatus Regenerative Technology Inc.
- Transcript : Biostage, Inc., Q1 2022 Earnings Call, May 17, 2022
